Mind.Px
Commercial- Indications
- Psoriasis
Company intelligence / Profile preview
Mindera Health’s lead product, Mind.Px™, has demonstrated clinical utility in a randomized prospective trial for psoriasis. The test enables prediction of patient response to expensive biologic drug classes prior to treatment selection. Clinical data show that use of the test leads to faster and more effective patient outcomes by guiding physicians toward the most appropriate therapy class from the outset, reducing trial-and-error prescribing and healthcare costs.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Mindera Health.